Maraviroc Waymade (Maraviroc)

Maraviroc is a CCR5‑targeting antiretroviral used in the management of HIV‑1 infection that utilizes the CCR5 co‑receptor pathway.

• Treatment‑experienced HIV‑1 infection with CCR5‑tropic virus: achieves viral suppression when added to a background regimen.
• Combination antiretroviral therapy for HIV‑1: contributes to overall reduction of viral load.
• Confirmed CCR5‑tropic HIV‑1 infection in any disease stage: helps maintain immune function alongside other agents.

• Maraviroc selectively binds to the CCR5 co‑receptor on CD4+ T cells, blocking the interaction between the receptor and the HIV‑1 envelope glycoprotein gp120. This prevents the virus from entering and infecting the host cell, thereby inhibiting replication of CCR5‑tropic HIV‑1 strains.

Common Side Effects

• Headache: mild to moderate discomfort reported by many patients.
• Nausea: occasional upset stomach, often transient.
• Diarrhea: loose stools that may resolve with continued therapy.
• Fatigue: feeling of tiredness without exertion.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Liver injury: signs of hepatitis or elevated enzymes.
• Severe allergic reaction: swelling, breathing difficulty, or hives.
• Depression or mood changes: new or worsening psychiatric symptoms.
• QT interval prolongation: potential cardiac rhythm disturbances.
• Stevens‑Johnson syndrome: rare but severe skin reaction.

Before initiating therapy, clinicians should consider the following precautions:

• Liver function monitoring: assess baseline enzymes and repeat periodically.
• Cardiovascular assessment: evaluate for existing heart disease or arrhythmias.
• Psychiatric evaluation: screen for depression or suicidal ideation.
• Hypersensitivity review: avoid in patients with known Maraviroc allergy.
• Pregnancy counseling: discuss potential risks and benefits; category B.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Maraviroc may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Maraviroc exposure.
• Protease inhibitors boosted with ritonavir: may increase plasma levels excessively.
• Certain anticonvulsants (e.g., phenobarbital): lower therapeutic effect.

Moderate Interactions (Monitor Closely)

• Statins (simvastatin, lovastatin): increased risk of myopathy.
• Antacids containing aluminum or magnesium: may affect absorption.
• Warfarin: monitor INR for potential anticoagulation changes.